Abstract:Acetylcholinesterase (AChE), a member of the α/β-hydrolase fold superfamily of proteins, is a serine hydrolase responsible for the hydrolysis of the well studied neurotransmitter acetylcholine (ACh). However, it is becoming clear that AChE has a range of actions other than this 'classical' role. Non-classical AChE functions have been identified in apoptosis, stress-responses, neuritogenesis, and neurodegeneration. Furthermore, these non-classical roles are attributable not only to the native protein, which app… Show more
“…Based on the circumstantial evidence linking AChE to ALS pathogenesis we sought to test the possibility that downregulation of AChE may be beneficial in an ALS mouse model. Because AChE may have noncatalytic effects [8, 9] together with the fact that AChE inhibition with drugs such as neostigmine (Neo) raise AChE levels [10], we chose to use antisense oligonucleotides (ASO) to AChE mRNA (mEN101) as our treatment drug. To address the possibility that mEN101's effect is mediated via a non-catalytic effect (i.e., reducing AChE levels) rather than via a decrease in catalytic activity, we compared mEN101 treatment to the AChE catalytic inhibitor Neo.…”
Objective. Previous research suggests that acetylcholinesterase (AChE) may be involved in ALS pathogenesis. AChE enzyme inhibitors can upregulate AChE transcription which in certain contexts can have deleterious (noncatalytic) effects, making them theoretically harmful in ALS, whilst AChE antisense-oligonucleotides (mEN101), which downregulate AChE may be beneficial. Our aim was to investigate whether downregulation of AChE using mEN101 is beneficial in an ALS mouse model. Methods. ALS (G93A-SOD1) mice received saline, mEN101, inverse-EN101, or neostigmine. Treatments were administered from 5 weeks. Disease-onset and survival were recorded. Additional mice were sacrificed for pathological analysis at 15 weeks of age. In a follow-up experiment treatment was started at the symptomatic stage at a higher dose. Results. mEN101 given at the presymptomatic (but not symptomatic) stage prolonged survival and attenuated motor-neuron loss in ALS mice. In contrast, neostigmine exacerbated the clinical parameters. Conclusions. These results suggest that AChE may be involved in ALS pathogenesis. The accelerated disease course with neostigmine suggests that any beneficial effects of mEN101 occur through a non-catalytic rather than cholinergic mechanism.
“…Based on the circumstantial evidence linking AChE to ALS pathogenesis we sought to test the possibility that downregulation of AChE may be beneficial in an ALS mouse model. Because AChE may have noncatalytic effects [8, 9] together with the fact that AChE inhibition with drugs such as neostigmine (Neo) raise AChE levels [10], we chose to use antisense oligonucleotides (ASO) to AChE mRNA (mEN101) as our treatment drug. To address the possibility that mEN101's effect is mediated via a non-catalytic effect (i.e., reducing AChE levels) rather than via a decrease in catalytic activity, we compared mEN101 treatment to the AChE catalytic inhibitor Neo.…”
Objective. Previous research suggests that acetylcholinesterase (AChE) may be involved in ALS pathogenesis. AChE enzyme inhibitors can upregulate AChE transcription which in certain contexts can have deleterious (noncatalytic) effects, making them theoretically harmful in ALS, whilst AChE antisense-oligonucleotides (mEN101), which downregulate AChE may be beneficial. Our aim was to investigate whether downregulation of AChE using mEN101 is beneficial in an ALS mouse model. Methods. ALS (G93A-SOD1) mice received saline, mEN101, inverse-EN101, or neostigmine. Treatments were administered from 5 weeks. Disease-onset and survival were recorded. Additional mice were sacrificed for pathological analysis at 15 weeks of age. In a follow-up experiment treatment was started at the symptomatic stage at a higher dose. Results. mEN101 given at the presymptomatic (but not symptomatic) stage prolonged survival and attenuated motor-neuron loss in ALS mice. In contrast, neostigmine exacerbated the clinical parameters. Conclusions. These results suggest that AChE may be involved in ALS pathogenesis. The accelerated disease course with neostigmine suggests that any beneficial effects of mEN101 occur through a non-catalytic rather than cholinergic mechanism.
“…Thus, in postnatal ontogenesis of hypoxic rats, the activity of acetyl-and butyrylcholinesterases (AChE and BChE) in the sensorimotor cortex had a significantly different dynamics compared to controls [68]. Apart from decreased activity of these enzymes during the first month of postnatal ontogenesis (and active formation of synaptic contacts), there were also significant changes in the distribution of the membrane-bound (involved in signal transduction) and soluble (participating in synaptogenesis [69]) forms of AChE. Moreover, with aging in rats subjected to prenatal hypoxia, there was an increase in the ratio of BChE in the total cholinesterase activity that could have a compensatory nature since this enzyme plays an important role in hydrolyzing various toxic agents, which might be produced by impaired brain tissue.…”
Section: Changes At the Molecular And Biochemical Levelsmentioning
This chapter summarizes the phylogenetic and ontogenetic approaches for studying cognitive disorders such as Alzheimer's disease. It gives an extended example of evaluation of animal behavior and brain properties using an original model of prenatal hypoxia in rats by various physiological, behavioral, immunohistochemical, molecular biological, and biochemical techniques at different stages of postnatal development, which provide a better understanding of the pathological processes in the human brain during the development of neurodegeneration.
“…In addition to the canonical role in termination of neural impulses by catalytic hydrolysis of acetylcholine, AChE in vertebrates is postulated to play many additional roles in physiology and development [35,36]. The presence of multiple genes encoding AChE in ticks may provide separation of structure and function (see Fig.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.